As of March 31, 2026, Precision had approximately $125.8 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, continued fiscal and operating discipline, and availability of Precision’s at-the-market facility will fund the Company’s cash runway through 2028. Based on its expected cash runway, Precision believes it is sufficiently capitalized to achieve PBGENE-HBV and PBGENE-DMD data milestones through 2028.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DTIL:
- Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year
- Precision BioSciences activates first clinical trial site for PBGENE-DMD
- Precision BioSciences announces oral presentation at ASGCT 2026
- Precision BioSciences announces grant of inducement awards
- Precision Bio’s 15-Year HBV Follow-Up Study: What Investors Should Know